4840 Lakeview Boulevard
Fremont, CA 94538
Phone: 510-226-3990

T. William Hutchens, CEO
Privately Held


Founded in 1999, LumiCyte uses its bioinformatics platform for proteomic drug discovery and disease diagnosis. The driving technology behind the company’s informatics platform is Surface-enhanced Laser Desorption/Ionization (SELDI), which uses pulses of laser light to read molecular profiles on chips and probes.

In August 2001, the company launched Seldiography protein discovery and validation services with the intention of entering into partnerships and collaborations with pharmaceutical and biotechnology companies that have drugs in development.

The company integrates information from genomics, proteomics and clinical sources with its protein biomarker profiles in its BioPhore Knowledgebase to eventually become a comprehensive source of human biofluid secreted protein knowledge.

Its patented biochips use plasma, saliva or urine to generate molecular protein information. LumiCyte’s scientists work with physicians to use biochips for early detection of disease and to monitor patient responses to treatment. It then uses its Utility-Driven Discovery strategy to discover alterations in protein profiles associated with changes in health status. It can move from discovery to high-throughput validation on the same biochips.


LumiCyte has collaborations with medical and academic institutions. Building on their previous discovery of a unique protein pattern in the serum of asymptomatic prostate cancer patients, LumiCyte is working with the National Cancer Institute and the FDA to validate protein biomarker profiles that have not previously been identified as biomarkers for prostate cancer.

The company has a strategic alliance with Kratos Analytical, a subsidiary of Shimadzu Corp., to utilize AXIMA-CFR mass spectrometry systems to populate its protein biochip data aggregation facilities worldwide. In addition, Kratos will invest in the development of specialized biochip readers to be used exclusively by LumiCyte to collect proteomics information.